It's fair to say that Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) are dominating the coronavirus vaccine market these days. Their vaccines have fully immunized 86 million and 62 million Americans, respectively. They both entered the market first, so they have an advantage over rivals from a timeline perspective.
Of course, that doesn't mean market dominance will last forever. Competition right now comes in the form of Johnson & Johnson (NYSE: JNJ) . And Novavax may be next to enter the market.
Still, one piece of recent news opens up new possibilities for Pfizer and Moderna. And it could very well hand the vaccine market over to them for the foreseeable future.
For further details see:
This News May Hand the Vaccine Market Over to Pfizer and Moderna